Final Results

Summary by AI BETAClose X

Scancell Holdings reported its business update and financial results for the year ended April 30, 2025. The company's operating loss was £15.0 million, compared to £18.3 million in the previous year. The group's cash balance at year-end was £16.9 million, up from £14.8 million. A financing in late 2024 raised gross proceeds of £11.3 million. A second commercial license with Genmab for SC2811 secured $6 million in total upfront payments and up to $630 million in potential milestones and low-single digit royalties. The Group's overall loss for 2025 was £12.3 million, compared to £5.9 million in 2024. The estimated cash runway of the Group is into the third calendar quarter of 2026.

Disclaimer*

UK 100

Latest directors dealings